(Kinki Region) Kansai Investment Promotion Seminar and Tour-Attractive Kansai, Japan's Capital of Biotechnology-“Forefront of Regenerative Medicine and Outlook of Pluripotent Stem Cells” (FY2010)
There are many outstanding companies, universities, and research institutes in the fields of biotechnology and medicine in the Kansai region. In Osaka, where many leading Japanese pharmaceutical companies have their main offices, several large foreign pharmaceutical companies from Britain or the United States have set up operations as well. In Saito, a newly developed “international culture park” in the northern part of Osaka Prefecture, Osaka University, a concentration of public research institutes, and a number of university-initiated biotech ventures are propering too. In Hyogo Prefecture, the Kobe Biomedical Innovation Cluster (KBIC) is taking shape, and many institutes are promoting the development of advanced medical technologies. Foreign companies are setting up operations there as well. And in Kyoto, there exist Kyoto University, which has a world-class iPS cell research institute and a concentration of well-established research institutes and companies in such fields as medical and diagnostic equipment and functional foods.
In these circumstances, this program aimed to promote the excellent research facilities and business environment in the Kansai region, especially in the fields of biotechnology and medicine, with a view to encouraging the secondary investment of foreign companies with operations in and around Tokyo.
Dates: December 9 (Thursday)-10 (Friday), 2010
Organized by: Kinki Bureau of Economy, Trade and Industry (Ministry of Economy, Trade and Industry), Institute for International Studies and Training (IIST), Council for INVEST Kansai, Japan External Trade Organization (JETRO), Osaka Office
December 9 seminar: 98 persons; December 10 tour: 30 persons (both full capacity)
In the seminar, Professor Ryuichi Morishita of the Osaka University Graduate School of Medicine, who is also a member of the board of AnGes MG, Inc., the first university- initiated venture company to be listed in Japan, introduced such topics as trends in cutting-edge medical technology in the biotech field, including regenerative medicine, and the potential of the Kansai biotech cluster; Professor Yoshiki Sawa of the Osaka University Graduate School of Medicine spoke about state-of-the-art regenerative medicine, citing the successful example of myocardial regenerative therapy in which cardiomyocyte sheet were used for the first time in the world for patients with critical heart failure; and Professor Yasuhiko Tabata of the Institute for Frontier Medical Sciences at Kyoto University explained, in a very easy-to-understand manner, about the application of manufacturing technology, such as material engineering, to enhance the natural healing power of cells and the potential of medical-industrial collaboration. In the tour on the following day, participants visited the Medical Center for Translational Research (MTR), Osaka University Hospital, the National Institute of Biomedical Innovation, and, inside Kyoto University, the Institute for Integrated Cell-Material Sciences (iCeMS) and the world-famous Center for iPS Cell Research and Application (CiRA) headed by Dr. Shinya Yamanaka. The participants listened attentively to the explanations of the latest developments in regenerative medicine, from cutting-edge treatment and front-line research to business use.
The principal objectives of this program were to disseminate information on the potential of biotech and medical industries in the Kansai region in order to attract secondary investment there of foreign companies already established in and around Tokyo.
International Exchange Dept.